EBR SYSTEMS INC (EBR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBR

EBR - EBR SYSTEMS INC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -1.17
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.16

02 Oct
2025

-0.010

OPEN

$1.20

-0.85%

HIGH

$1.20

821,838

LOW

$1.14

TARGET
$2.555 120.3% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
EBR: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) - 18.0 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 20202021202220232024
EPS Basic xxxxxxxxxxxx-19.0
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxx10.6
Net Operating Cash Flow xxxxxxxxxxxx-62.5 M
Net Profit Margin xxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20202021202220232024
Return on Capital Employed xxxxxxxxxxxx-145.79 %
Return on Invested Capital xxxxxxxxxxxx-58.53 %
Return on Assets xxxxxxxxxxxx-52.77 %
Return on Equity xxxxxxxxxxxx-145.79 %
Return on Total Capital xxxxxxxxxxxx-54.63 %
Free Cash Flow ex dividends xxxxxxxxxxxx-62.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20202021202220232024
Short-Term Debt xxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxx66 M
Total Debt xxxxxxxxxxxx67 M
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx98 M
Price To Book Value xxxxxxxxxxxx9.67

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20202021202220232024
Capex xxxxxxxxxxxx0.4 M
Capex % of Sales xxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxx1 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx57 M
Research & Development xxxxxxxxxxxx41 M
Investments - Total xxxxxxxxxxxx9 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

14/08/2025

1

Buy

$2.86

146.55%

Morgans assesses EBR Systems' 2Q25 result as in-line, with net loss of -US$12m but cash used for operations down -US$2m on lower R&D spend.

The highlight was US$150,000 revenue in June from first three WiSE CRT devices placed in two US hospitals. Patient and physician feedback were positive but reimbursement is still expected later this year.

The broker sees the company's rollout strategy as prudent with limited market release in 4Q25, and full commercial launch in FY26.

Earnings forecasts for FY25-27 cut on lower sales forecasts but outer years retained.

Buy. Target unchanged at $2.86.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -19.27 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -11.47 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

16/09/2025

1

Overweight

$3.00

158.62%

Wilsons notes EBR Systems' confirmed first 3 commercial implants of its Wise-CRT device and expects a modest uptick from next month when reimbursement incentives kick in. The target net average selling price of US$45k is well supported in the broker's view.

The broker's forecast for FY26 is for the sale of 436 systems based on an average of one case/week across 16 implanting centres. Expectation is for migration from inpatient to outpatient procedures to drive medium-term volume acceleration.

The broker will watch for clinical research and peer-reviewed studies for signs of broader electrophysiologist-driven adoption.

Overweight. Target unchanged at $3.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -19.27 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -18.18 cents.
Access Extra Coverage Research History >

EBR STOCK CHART

FNArena News on EBR

Latest Medical Equipment & Devices News

1
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
2
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
3
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
4
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
5
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
6
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
7
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
8
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
9
Breakout For Cochlear

Aug 10 2021 - Technicals
10
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia